Mednet Logo
Community

For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?

STS was approved in 2022 in the US to reduce risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic tumors. Have you expanded to using in other populations?
Community PollStarted

For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?

24 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet Member
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Children's Hospital Los Angeles
Answered on

Sodium thiosulfate (STS) is approved in the US (FDA) and Europe (EMA) for the prevention of cisplatin-induced hearing loss (CIHL) in patients 1 month and older treated with cisplatin for any type of cancer. Although intravenous STS has not been subjected to a randomized clinical trial for patients >...

Join for free or sign in to see the full answer